RCGP questions scorecard introduction

 The Royal College of General Practitioners (RCGP) has queried the introduction of an innovation scorecard insisting it will not improve standards of patient care.

Chair Professor Clare Gerada (pictured) has revealed her scepticism towards the plans which would make it compulsory for NHS Trusts to have NICE recommended products on their formulary.

But Professor Gerada said that the scorecard focuses on individual diseases and not the complex patients that GPs see on a daily basis.

She said: “While it’s important that we follow best practice, we need to be allowed to do things if we know they’re in the best interests of patients.”

Dr Gerada added that the DH should allow doctors to express their professionalism instead of “monitoring everything that can be monitored.”

RCGP Deputy Chairman Dr Richard Vautrey said than an innovation scorecard would only work if resources were in place for the NHS to fund every drug recommended by NICE. “All it is going to indicate is which CCGs have the funding available,” he said.

“It is disingenuous of the NHS Commissioning Board to suggest that CCGs can provide every drug NICE recommends.”

The DH has told CCGs to start working with PCT pharmacies to remove any drugs which are recommended by NICE from local treatment ‘blacklists’ as part of measures to introduce the scorecard.

An earlier study by GPOnline found that one PCT in four was blacklisting drugs recommended by NICE.